SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-039395
Filing Date
2023-08-08
Accepted
2023-08-08 08:21:08
Documents
84
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fusn-20230630.htm   iXBRL 10-Q 3153291
2 EX-31.1 fusn-ex31_1.htm EX-31.1 20396
3 EX-31.2 fusn-ex31_2.htm EX-31.2 20393
4 EX-32.1 fusn-ex32_1.htm EX-32.1 11220
5 EX-32.2 fusn-ex32_2.htm EX-32.2 12028
  Complete submission text file 0000950170-23-039395.txt   12677525

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fusn-20230630_def.xml EX-101.DEF 214515
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fusn-20230630.xsd EX-101.SCH 76687
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fusn-20230630_lab.xml EX-101.LAB 590297
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fusn-20230630_pre.xml EX-101.PRE 419274
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fusn-20230630_cal.xml EX-101.CAL 62059
78 EXTRACTED XBRL INSTANCE DOCUMENT fusn-20230630_htm.xml XML 2798787
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39344 | Film No.: 231149467
SIC: 2836 Biological Products, (No Diagnostic Substances)